Relevance of breast cancer subtypes for magnetic resonance imaging response monitoring during neoadjuvant chemotherapy.
Changes in magnetic resonance imaging (MRI) during neoadjuvant chemotherapy (NAC) have been reported as predictive of pathology outcome in triple-negative and HER2-positive breast cancer. The purpose of our study was to evaluate the relevance of breast cancer subtype for MRI response in 24 women before and during NAC in our centre. Our results show that a reduction greater than 23% is associated with a pathological complete response (pCR) in Her-2-positive and ER-negative/Her2-negative breast cancer, and suggest a trend correlation between higher ADC values and pCR in these subtypes in comparison with ER-positive/Her2-negative breast cancers. Higher proliferating tumours respond better to chemotherapy and our study suggests that changes in MRI during NAC are predictive of pCR in these breast cancer subtypes.
Department of Medical Oncology, Hospital Universitario Infanta Sofía, Paseo de Europa, 34, ES-28702 San Sebastián de los Reyes, Madrid, Spain. c_gomezraposo@hotmail.com
Cesar
C
Gómez-Raposo
Mónica
M
Andreu
Inés
I
Suárez-García
M Isabel
MI
Esteban
Mar
M
Carballo
María F
MF
Sereno-Moyano
José L
JL
Vázquez Osorio
Javier
J
Heras
Francisco
F
Zambrana Tévar
Eva
E
Pelayo
Miriam
M
López-Gómez
Clara
C
García de Santiago
María
M
Merino Salvador
Enrique
E
Casado
D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human